Talphera (NASDAQ:TLPH) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Talphera (NASDAQ:TLPH) announced its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03, Zacks reports.

Here are the key takeaways from Talphera’s conference call:

• Talphera said the NEPHRO CRRT study is progressing well, with enrollment now well above the 50% milestone and the company still expecting to complete enrollment in 2026.
• Management reiterated plans to file the PMA in 2026 and still targets a potential Niyad approval in 2027, saying the company is positioned for that timeline.
• The company said it does not plan additional enrollment updates before study completion; it expects to announce last patient out, then release top-line data within about a month afterward.
• Talphera ended the quarter with $21.1 million in cash and said that, along with future conditional tranches, should fund operations through at least a potential PMA approval next year.
• Cash operating expenses rose to $3.9 million from $2.9 million a year ago, driven mainly by higher Niyad development spending and some increased G&A costs.

Talphera Price Performance

Shares of TLPH stock traded up $0.04 on Wednesday, hitting $0.90. 142,385 shares of the stock traded hands, compared to its average volume of 218,790. Talphera has a 52 week low of $0.38 and a 52 week high of $1.57. The firm has a 50 day simple moving average of $0.81 and a two-hundred day simple moving average of $1.00. The firm has a market cap of $46.78 million, a price-to-earnings ratio of -2.44 and a beta of 0.79.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Westpark Capital started coverage on Talphera in a research report on Thursday, April 30th. They issued a “buy” rating and a $3.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research report on Monday, April 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $3.00.

Insider Activity

In other Talphera news, CFO Raffi Asadorian purchased 45,000 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was acquired at an average price of $0.81 per share, for a total transaction of $36,450.00. Following the purchase, the chief financial officer owned 91,256 shares of the company’s stock, valued at approximately $73,917.36. This represents a 97.28% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Badri N. Dasu purchased 35,000 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were acquired at an average cost of $0.81 per share, for a total transaction of $28,350.00. Following the completion of the acquisition, the insider owned 76,230 shares of the company’s stock, valued at approximately $61,746.30. This trade represents a 84.89% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 433,674 shares of company stock worth $304,348. 3.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Talphera

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC lifted its holdings in Talphera by 75.3% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after purchasing an additional 1,500,000 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in shares of Talphera during the fourth quarter valued at approximately $658,000. Geode Capital Management LLC raised its position in shares of Talphera by 107.0% during the fourth quarter. Geode Capital Management LLC now owns 342,987 shares of the company’s stock valued at $391,000 after buying an additional 177,294 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Talphera by 412.6% in the fourth quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock worth $293,000 after buying an additional 207,166 shares in the last quarter. Finally, Diadema Partners LP purchased a new position in shares of Talphera in the fourth quarter worth $156,000. Institutional investors own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.